// App-Quantinova.ai

: Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.

Researchers

Presenter

  • Claudia A.M. Fulgenzi

Principal Investigators

  • James Korolewicz

  • Antonio D'Alessio

  • Bernhard Scheiner

  • Charalampos-Vlasios Stikas

  • Alessandra Gennari

  • Alessio Cortellini

  • Lorenza Scotti

  • David J. James Pinato

Medical Centers

  • Universita del Piemonte Orientale, Novara, Italy

  • Department of Surgery & Cancer, Imperial College London, London, United Kingdom

  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

  • Imperial College, London, United Kingdom

  • Università del Piemonte Orientale - Dipartimento di Medicina Traslazionale - DIMET, Novara, Italy

Locations

  • Austria

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Tislelizumab

  • Cabozantinib

  • Ticilimumab

  • Camrelizumab

  • Bevacizumab

  • Durvalumab

  • Lenvatinib

  • Sintilimab

  • Linifanib

  • Nivolumab

  • Sunitinib

  • Sorafenib

  • brivanib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved